
Loading, please wait...

Loading, please wait...

A significant surge of Kala-azar in Kenya, also known as visceral leishmaniasis, has led to a record number of deaths and a growing public health crisis. This deadly, neglected tropical disease presents a major challenge to healthcare systems in East Africa. For example, one 60-year-old grandmother's health deteriorated for nearly a year due to repeated misdiagnoses of malaria and dengue fever before she received the correct treatment.
Kala-azar, which sandflies spread, carries an extremely high fatality rate. If left untreated, patients face a 95% mortality risk. The disease causes severe fever, significant weight loss, and the enlargement of both the spleen and liver. East Africa historically accounts for over two-thirds of all global cases. Consequently, the recent spike in Kenya is a major concern.
Early diagnosis of visceral leishmaniasis remains a critical barrier to effective treatment. Moreover, initial symptoms often mimic common endemic diseases like malaria or dengue fever, leading local practitioners to make dangerous diagnostic mistakes. Patients in Mandera county, a parasite hotspot, have had to rely on under-equipped local facilities. This reliance often results in incorrect treatment, which allows the disease to progress to a fatal stage. The harsh treatment process, even when eventually administered, can leave patients with serious complications, like the hearing problems one patient experienced.
Health ministry data shows a worrying increase in case numbers. Cases spiked dramatically from 1,575 in 2024 to 3,577 in 2025. This rapid growth highlights the urgency of the crisis. Regional countries adopted a framework in Nairobi in 2023 to eliminate the disease by 2030, but current resource gaps undermine this goal.
The disease is now spreading to regions previously untouched, becoming endemic in new areas. Health officials state that two main factors drive this expansion: changing climatic conditions and expanding human settlements. Experts, like Dr. Cherinet Adera, confirm that climate change expands the geographical range of the sandflies, increasing outbreak risks in new areas. Sandflies commonly shelter in soil fissures, anthills, and cracks in poorly plastered mud houses, multiplying rapidly during the rainy season that follows a prolonged drought. Therefore, the devastating drought in northeastern Kenya and neighboring Ethiopia and Somalia directly contributes to the current crisis.
Furthermore, socioeconomic factors exacerbate the situation. Kala-azar primarily affects the poorest members of the community. Malnutrition and weak immunity significantly increase susceptibility to the infection and worsen patient outcomes. For instance, a surge among migrant workers at a quarry site last year resulted in multiple deaths, highlighting the vulnerability of displaced and mobile populations.
Kenya's healthcare infrastructure currently struggles to manage this surge. Few facilities possess the capability to actively diagnose and treat Kala-azar. Dr. Paul Kibati points out that mistakes in testing and treatment can prove fatal. Consequently, health organizations require more extensive training for personnel in endemic areas. The standard treatment regimen involves daily injections and sometimes blood transfusions, lasting up to 30 days. This regimen is expensive, costing up to 100,000 Kenyan shillings ($775) just for the treatment itself, excluding drug costs. Facilities must become adequately equipped to handle the complex and costly treatment.
Q1: What are the primary symptoms of Kala-azar?
Visceral leishmaniasis typically presents with irregular bouts of fever, significant weight loss, and the enlargement of the spleen and liver.
Q2: How does climate change influence the spread of Kala-azar?
Changing climatic conditions, such as cycles of drought followed by rain, expand the sandfly's range. Therefore, new areas become ideal breeding grounds for the vector, moving the disease into previously unaffected communities.
Q3: What is the estimated fatality rate of untreated Kala-azar?
Untreated Kala-azar has a very high fatality rate, sometimes reaching 95% or higher, often within two years of onset. Early diagnosis and prompt, effective treatment are essential to prevent death.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


Kenya is battling a severe Kala-azar (Visceral Leishmaniasis) surge, driven by climate change and poor diagnosis. Cases doubled, straining limited, costly t...
7 months ago

Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today

A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today

Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today

Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday

Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today